ALK-positive Non-small Cell Lung Cancer (NSCLC)
Oncology
Prevalence
75.0 / 100K
Incidence
47.0 / 100K/yr
0 drugs in development·0 companies·1 clinical trial
Frequently asked questions
How many clinical trials target ALK-positive Non-small Cell Lung Cancer (NSCLC)?
There are 1 clinical trial targeting ALK-positive Non-small Cell Lung Cancer (NSCLC) tracked by BioSniper.
What is the prevalence of ALK-positive Non-small Cell Lung Cancer (NSCLC)?
The estimated prevalence of ALK-positive Non-small Cell Lung Cancer (NSCLC) is approximately 75.0 per 100,000 population.
Deep-dive into ALK-positive Non-small Cell Lung Cancer (NSCLC)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis